Summary:
This is a clinical research study of an investigational medication, EPI-7386, for patients with metastatic castrate resistant prostate cancer. The investigational medication will be given together with enzalutamide in order to test the effectiveness of the combination of EPI-7386 and enzalutamide versus enzalutamide alone.
Partial Criteria:
- Have rising PSA levels
- Be 18 years or older
- Diagnosed with metastatic castrate resistant prostate cancer
- Willing to complete monthly visits in clinic
- Willing to sign an informed consent
- Meets study participation requirements as outlined and reviewed by study doctor